{"title":"局部前列腺癌:化疗的未来治疗策略","authors":"K. Fizazi , A. Descazeaud","doi":"10.1016/S0003-4401(07)80514-6","DOIUrl":null,"url":null,"abstract":"<div><p>Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009–2010.</p></div>","PeriodicalId":50783,"journal":{"name":"Annales D Urologie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2007-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0003-4401(07)80514-6","citationCount":"0","resultStr":"{\"title\":\"Cancer de la prostate Iocalisé : futures stratégies de prise en charge par chimiothérapie\",\"authors\":\"K. Fizazi , A. Descazeaud\",\"doi\":\"10.1016/S0003-4401(07)80514-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009–2010.</p></div>\",\"PeriodicalId\":50783,\"journal\":{\"name\":\"Annales D Urologie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S0003-4401(07)80514-6\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales D Urologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0003440107805146\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales D Urologie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003440107805146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cancer de la prostate Iocalisé : futures stratégies de prise en charge par chimiothérapie
Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009–2010.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
